DY

Dharaba Yashdipsinh Gohil

Active Director Designated Partner DIN 10816351
DIN 10816351 First appointment Oct 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Dharaba Yashdipsinh Gohil

Data last updated:

Dharaba Yashdipsinh Gohil is a Designated Partner at Acceltrials Clinical Research Solutions Llp (since 2024).

DIN 10816351
Primary Designation Designated Partner
First Appointment 21 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner21 Oct 20242024Active

Board colleagues of Dharaba Yashdipsinh Gohil

NameDINCompanyDesignation
Dipsa Gautambhai Patel10816352Acceltrials Clinical Research Solutions LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Acceltrials Clinical Research Solutions Llp
Premium access

Shareholding and investment profile for Dharaba Yashdipsinh Gohil

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dharaba Yashdipsinh Gohil

Dharaba Yashdipsinh Gohil currently holds 1 directorship: Acceltrials Clinical Research Solutions Llp (Designated Partner, since 21 Oct 2024).

Dharaba Yashdipsinh Gohil was first appointed on 21 Oct 2024 as Designated Partner at Acceltrials Clinical Research Solutions Llp.

The current boards of Dharaba Yashdipsinh Gohil's companies include Dipsa Gautambhai Patel (Acceltrials Clinical Research Solutions Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available